WO2003070969A3 - Inhibition de l'expression du gene bcl2 induite par interference arn au moyen de petits acides nucleiques interferents (sina) - Google Patents

Inhibition de l'expression du gene bcl2 induite par interference arn au moyen de petits acides nucleiques interferents (sina) Download PDF

Info

Publication number
WO2003070969A3
WO2003070969A3 PCT/US2003/004908 US0304908W WO03070969A3 WO 2003070969 A3 WO2003070969 A3 WO 2003070969A3 US 0304908 W US0304908 W US 0304908W WO 03070969 A3 WO03070969 A3 WO 03070969A3
Authority
WO
WIPO (PCT)
Prior art keywords
bcl2
nucleic acid
gene expression
rna
bcl
Prior art date
Application number
PCT/US2003/004908
Other languages
English (en)
Other versions
WO2003070969A2 (fr
Inventor
James Mcswiggen
Leonid Beigelman
Original Assignee
Sirna Therapeutics Inc
James Mcswiggen
Leonid Beigelman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirna Therapeutics Inc, James Mcswiggen, Leonid Beigelman filed Critical Sirna Therapeutics Inc
Priority to JP2003569860A priority Critical patent/JP2005517452A/ja
Priority to CA002463595A priority patent/CA2463595A1/fr
Priority to EP03709164A priority patent/EP1442143A4/fr
Priority to AU2003213119A priority patent/AU2003213119A1/en
Publication of WO2003070969A2 publication Critical patent/WO2003070969A2/fr
Publication of WO2003070969A3 publication Critical patent/WO2003070969A3/fr
Priority to US10/923,516 priority patent/US20050176025A1/en
Priority to US12/192,878 priority patent/US20090247613A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)

Abstract

La présente invention concerne des techniques et des réactifs qui conviennent pour moduler l'expression du gène BCL2 dans diverses applications comprenant l'utilisation de ces techniques et de ces réactifs dans une validation de cible thérapeutique et diagnostique et dans des applications de recherche génomique. Cette invention concerne spécifiquement de petites molécules d'acide nucléique telles que de petites molécules d'acide nucléique interférent (siNA), de petites molécules d'ARN interférent (siRNA), des molécules d'ARN double brin (dsRNA), des micro-ARN (miRNA),et de petites molécules d'ARN en épingle à cheveux (shRNA) capables d'induire une interférence ARN (RNAi) contre l'expression des gènes BCL2, BCL-XL, MCL-1, BCL2-Ll, CED-9, BAG-1, ElB-194 et/ou BCL-A. Ces petites molécules conviennent pour le traitement du cancer et d'autres pathologies qui répondent à la modulation de l'expression de BCL2, BCL-XL, MCL-1, BCL2-Ll, CED-9, BAG-1, E1B-194 et/ou BCL-A1.
PCT/US2003/004908 2001-05-18 2003-02-18 Inhibition de l'expression du gene bcl2 induite par interference arn au moyen de petits acides nucleiques interferents (sina) WO2003070969A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2003569860A JP2005517452A (ja) 2002-02-20 2003-02-18 短干渉核酸（ｓｉＮＡ）を用いるＢＣＬ２遺伝子発現のＲＮＡ干渉媒介性阻害
CA002463595A CA2463595A1 (fr) 2002-02-20 2003-02-18 Inhibition de l'expression du gene bcl2 induite par interference arn au moyen de petits acides nucleiques interferents (sina)
EP03709164A EP1442143A4 (fr) 2002-02-20 2003-02-18 Inhibition de l'expression du gene bcl2 induite par interference arn au moyen de petits acides nucleiques interferents (sina)
AU2003213119A AU2003213119A1 (en) 2002-02-20 2003-02-18 RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US10/923,516 US20050176025A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
US12/192,878 US20090247613A1 (en) 2002-02-20 2008-08-15 RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US35858002P 2002-02-20 2002-02-20
US60/358,580 2002-02-20
US36312402P 2002-03-11 2002-03-11
US60/363,124 2002-03-11
US38678202P 2002-06-06 2002-06-06
US60/386,782 2002-06-06
US39690502P 2002-07-18 2002-07-18
US60/396,905 2002-07-18
US40678402P 2002-08-29 2002-08-29
US60/406,784 2002-08-29
US40837802P 2002-09-05 2002-09-05
US60/408,378 2002-09-05
US40929302P 2002-09-09 2002-09-09
US60/409,293 2002-09-09
US44012903P 2003-01-15 2003-01-15
US60/440,129 2003-01-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/923,516 Continuation-In-Part US20050176025A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)

Publications (2)

Publication Number Publication Date
WO2003070969A2 WO2003070969A2 (fr) 2003-08-28
WO2003070969A3 true WO2003070969A3 (fr) 2004-01-08

Family

ID=27761716

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/004908 WO2003070969A2 (fr) 2001-05-18 2003-02-18 Inhibition de l'expression du gene bcl2 induite par interference arn au moyen de petits acides nucleiques interferents (sina)

Country Status (5)

Country Link
EP (1) EP1442143A4 (fr)
JP (1) JP2005517452A (fr)
AU (1) AU2003213119A1 (fr)
CA (1) CA2463595A1 (fr)
WO (1) WO2003070969A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9399774B2 (en) 2010-04-29 2016-07-26 Ionis Pharmaceuticals, Inc. Modulation of transthyretin expression

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
DE10163098B4 (de) 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
DE10202419A1 (de) 2002-01-22 2003-08-07 Ribopharma Ag Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US7635770B2 (en) 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
US7592442B2 (en) 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US7977471B2 (en) 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7691998B2 (en) 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
WO2006006948A2 (fr) 2002-11-14 2006-01-19 Dharmacon, Inc. Methodes et compositions permettant de selectionner des arnsi presentant une fonctionnalite amelioree
US7619081B2 (en) 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US8090542B2 (en) 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
GB0306148D0 (en) * 2003-03-18 2003-04-23 Milner Jo Regulation of gene expression
WO2004106511A1 (fr) * 2003-05-30 2004-12-09 Nippon Shinyaku Co., Ltd. Arn oligobicatenaire inhibant l'expression de bcl-2 et composition medicinale contenant cet arn
WO2005061710A1 (fr) * 2003-12-23 2005-07-07 Santaris Pharma A/S Composes oligomeres permettant la modulation de bcl-2
US20050244869A1 (en) 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
US7605250B2 (en) 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
WO2006035432A2 (fr) * 2004-09-27 2006-04-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Silençage genique s'utilisant en dermatologie
CN103028120B (zh) * 2005-09-12 2015-08-12 俄亥俄州立大学研究基金会 用于诊断或治疗bcl2相关癌症的组合物和方法
EP2468891B1 (fr) 2006-01-05 2015-04-29 The Ohio State University Research Foundation Procédés à base de micro ARN pour le diagnostic du cancer de la prostate ou de l'estomac.
EP2369011A1 (fr) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Empreintes digitales micro-ARN pendant une mégacaryocytopoïese
AU2007296055A1 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
CA2664271A1 (fr) * 2006-11-27 2008-06-12 Enzon Pharmaceuticals, Inc. Conjugues d'arn a interference courte polymeres
JP2010519910A (ja) * 2007-03-02 2010-06-10 エムディーアールエヌエー，インコーポレイテッド Ｂｃｌ２遺伝子の発現を抑制するための核酸化合物およびその使用
WO2008124927A1 (fr) * 2007-04-13 2008-10-23 Vincent Research & Consulting Inc. Siarn contre la thymidylate synthase et son utilisation dans les schémas de traitement du cancer
ES2570359T3 (es) 2007-08-03 2016-05-18 Univ Ohio State Res Found Regiones ultraconservadas que codifican ARNnc
US20110118337A1 (en) * 2008-07-10 2011-05-19 Merck Sharp & Dohme Corp. Method of Using Compositions Comprising MIR-192 and/or MIR-215 for the Treatment of Cancer
WO2010021389A1 (fr) * 2008-08-21 2010-02-25 協和発酵キリン株式会社 Acide nucléique capable d'inhiber l'expression de la protéine bcl-2
GB2468477A (en) * 2009-03-02 2010-09-15 Mina Therapeutics Ltd Double stranded RNA molecule comprising siRNA and miRNA precursors
US8916533B2 (en) 2009-11-23 2014-12-23 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
CN103140582A (zh) 2010-08-24 2013-06-05 默沙东公司 含有内部非核酸间隔子的单链RNAi试剂
WO2012058210A1 (fr) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA)
EP2637673B1 (fr) 2010-11-12 2016-10-26 The Ohio State University Research Foundation Procédés relatifs aux microarn-21 et réparation de désappariement dans le cancer colorectal
EP2640368B1 (fr) 2010-11-15 2020-12-30 The Ohio State University Research Foundation Systèmes mucoadhésifs à libération contrôlée
AU2012323924A1 (en) 2011-10-14 2014-05-29 The Ohio State University Methods and materials related to ovarian cancer
US9481885B2 (en) 2011-12-13 2016-11-01 Ohio State Innovation Foundation Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis
JP2015511121A (ja) 2012-01-20 2015-04-16 ジ・オハイオ・ステート・ユニバーシティ 浸潤性および予後に関する乳がんバイオマーカーシグネチャー
US9404108B2 (en) 2012-03-04 2016-08-02 Bonac Corporation Micro-RMA inhibitor
WO2014054927A1 (fr) 2012-10-05 2014-04-10 (주)바이오니아 Oligo-arn double hélice spécifique de l'amphiréguline, structure en double hélice d'oligo-arn comprenant ledit oligo-arn double hélice et composition destinée à prévenir ou traiter les maladies respiratoires en contenant
KR20150087270A (ko) * 2012-11-05 2015-07-29 프로나이 테라퓨틱스, 인코포레이티드 Bcl2 발현 조절에 의한 암치료용 바이오마커 이용 방법
JP6426268B2 (ja) 2014-04-04 2018-11-21 バイオニア コーポレーションＢｉｏｎｅｅｒ Ｃｏｒｐｏｒａｔｉｏｎ 新規の二重らせんオリゴｒｎａおよびこれを含む線維症または呼吸器疾患の予防または治療用薬学組成物
KR101993377B1 (ko) * 2017-07-20 2019-06-26 (주)큐리진 Bcl2 유전자 및 bi-1 유전자의 발현을 동시에 억제하는 핵산
US20220016156A1 (en) * 2018-12-05 2022-01-20 Nitto Denko Corporation Rnai molecule for treating cancer
CN113677373A (zh) * 2019-03-28 2021-11-19 日东电工株式会社 RNAi分子

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US6414134B1 (en) * 1988-12-22 2002-07-02 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US7662791B2 (en) * 2000-08-02 2010-02-16 University Of Southern California Gene silencing using mRNA-cDNA hybrids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414134B1 (en) * 1988-12-22 2002-07-02 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FIRE A. ET AL.: "Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans", NATURE, vol. 391, 19 February 1998 (1998-02-19), pages 806 - 811, XP002095876 *
NYKANEN A. ET AL.: "ATP requirements and small interfering RNA structure in the RNA interference pathway", CELL, vol. 107, 2 November 2001 (2001-11-02), pages 309 - 321, XP002969117 *
See also references of EP1442143A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9399774B2 (en) 2010-04-29 2016-07-26 Ionis Pharmaceuticals, Inc. Modulation of transthyretin expression

Also Published As

Publication number Publication date
AU2003213119A1 (en) 2003-09-09
WO2003070969A2 (fr) 2003-08-28
CA2463595A1 (fr) 2003-08-28
EP1442143A4 (fr) 2005-02-16
JP2005517452A (ja) 2005-06-16
EP1442143A2 (fr) 2004-08-04

Similar Documents

Publication Publication Date Title
WO2003070969A3 (fr) Inhibition de l'expression du gene bcl2 induite par interference arn au moyen de petits acides nucleiques interferents (sina)
CY1120292T1 (el) ΔΙΑΜΕΣΟΛΑΒΟΥΜΕΝΗ ΑΠΟ RNA ΠΑΡΕΜΒΟΛΗ ΑΝΑΣΤΟΛΗ ΤΗΣ ΓΟΝΙΔΙΑΚΗΣ ΕΚΦΡΑΣΗΣ ΧΡΗΣΙΜΟΠΟΙΩΝΤΑΣ ΒΡΑΧΥ ΠΑΡΕΜΒΑΛΛΟΜΕΝΟ ΝΟΥΚΛΕΪΚΟ ΟΞΥ (siNA)
WO2003072705A3 (fr) Inhibition a mediation d'arn de l'expression genique de la cycline d1 a l'aide d'acide nucleique a courte interference (sina)
WO2003070884A3 (fr) Inhibition de l'expression du gene de la mdr p-glycoproteine induite par l'interference d'arn, au moyen d'acide nucleique interferant court (sina)
WO2003070918A3 (fr) Inhibition mediee par interference arn d'une expression genique faisant appel a des acides nucleiques interferants courts chimiquement modifies (sina)
WO2003070881A3 (fr) Inhibition de l'expression genique de la proteine typrosine phoshatase-1b (ptb-1b) induite par l'interference arn, utilisant un acide nucleique d'interference court (sina)
WO2003070887A3 (fr) Inhibition mediee par interference d'arn de l'expression du gene de la proteine ezh2 du groupe polycomb a l'aide d'un acide nucleique court interferent (sina)
EP1522583A3 (fr) Inhibition au moyen de l'interférence par l'ARN de l'expression du gène du Placental growth factor à l'aide de courts acides nucléiques interférants
WO2003070896A3 (fr) Inhibition, induite par adn d'interference, de l'expression genique d'un antigene nucleaire de proliferation cellulaire (pcna) a l'aide d'un acide nucleique a interference courte (sina)
WO2003070197A3 (fr) Inhibition induite par l'interference d'arn de l'expression genique du recepteur du tgf-beta et du tgf-beta a l'aide d'un petit acide nucleique interferant (sina)
EP1710307A3 (fr) Interférence ARN permettant d'inhiber l'expression d'un gène à l'aide d'un acide nucléique interférant court (siNA)
WO2003070885A3 (fr) Inhibition mediee de l'interference d'arn de l'expression du gene de la stearoyl-coa desaturase (scd) au moyen d'acides nucleiques d'interference courts

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003709164

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2463595

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003213119

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003569860

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003709164

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10923516

Country of ref document: US